Guggenheim analyst Subbu Nambi initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $32 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
- Caris Life Sciences publishes Assure liquid biopsy platform study
- Caris Life Sciences vice chairman Brille buys 30,000 common shares
- Opening Day: Caris jumps as investors buy into ‘AI TechBio company’
- Two new option listings and nine option delistings on June 23rd